Watching
PAYS · Paysign, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 9 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A weekly close below $12.00, under the 50-day moving average and giving back most of the September advance. Separately, a reported 30 September 2026 active-program count below 165, the low end of guidance, would break the operating case.
Open pick Medium conviction, opened at $14.23. Since then +8.0% against the S&P 500's +1.2% (+6.8 pp). Kill line at open: $12.00 (weekly close); graded by at the latest.
How picks are graded →The thesis
Paysign's patient-affordability business, which runs copay-assistance programs for drug makers, keeps growing fast enough to hold the shares at their high. The third-quarter report settles it. Third-party calendars place the report between 10 November 2026 and 12 November 2026. It will show whether active programs reached the 165–170 management guided for 30 September 2026.
Since the 7 October 2026 note, the shares have set a new high. Adjusted daily closes show $14.96 on 8 October 2026, a 52-week closing high, above the $14.81 close of 5 October 2026. MarketBeat recorded an intraday high of $15.09 that day, the first trade above the $15.00 consensus analyst target. No new company release, analyst action or SEC filing has appeared since D.A. Davidson's target raise on 30 September 2026.
The narrative is maturing: two firms lifted targets to $15 in September, and the shares reached that level on 8 October 2026 with no company news since August. The case still rests on one strong quarter and a raised guide. The November report tests both, and it falls just outside the next 30 days.
Bullish and bearish views on Paysign, Inc.
The bull case on Paysign, Inc. (PAYS), in brief: Pharmaceutical revenue nearly doubled. The bear case: The price now sits at analyst targets.
Bull case
- Pharmaceutical revenue nearly doubled. The 5 August 2026 release reported second-quarter pharmaceutical revenue of $14.65 million, up 88.9% year over year. Active patient-affordability programs reached 148 at 30 June 2026, up from 97 a year earlier.
- Full-year guidance moved up sharply. On 5 August 2026 Paysign raised 2026 revenue guidance to $114.0–117.0 million from $106.5–110.5 million. It raised GAAP (generally accepted accounting principles) earnings per share guidance to $0.35–0.37 from $0.21–0.26.
- The company keeps beating estimates. Second-quarter revenue of $28.25 million beat the $26.35 million consensus, and GAAP earnings per share of $0.11 beat the $0.06 estimate, per the 5 August 2026 release and Benzinga.
- The third-quarter guide is specific. Management guided third-quarter revenue of $28.5–30.0 million, net income of $5.7–6.0 million and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $9.5–10.0 million on 5 August 2026.
- Analysts are extending forecasts. D.A. Davidson raised its target to $15 from $12 on 30 September 2026, per Investing.com, and introduced 2028 forecasts. Lake Street raised its target to $15 from $13 on 15 September 2026.
- The balance sheet carries no debt. The second-quarter release reported $27.37 million of unrestricted cash and no debt.
Bear case
- The price now sits at analyst targets. The $14.96 close on 8 October 2026 is level with the $15 targets from D.A. Davidson and Lake Street and the $15.00 consensus MarketBeat listed that day. Further gains likely need new target raises or a quarter above guidance.
- Momentum readings are stretched. The 14-day relative strength index (RSI), where readings above 70 are commonly read as overbought, stood at 77.1 on 8 October 2026. The shares rose 64.0% over the three months to that date.
- Insiders have sold into the rally. MarketBeat counted 444,904 shares, worth about $5.3 million, sold by insiders over the latest 90 days. Chief Financial Officer Jeffery Baker sold 35,000 shares on 12 August 2026, and Chief Innovation Officer Michael Ngo's Form 4 filed 10 September 2026 reported 150,000 shares sold on 8 September 2026 and 9 September 2026.
- The valuation already prices in growth. MarketBeat listed a price-to-earnings ratio of 57.50 and a market value of $844.08 million on 8 October 2026.
- The plasma business is shrinking in footprint. The second-quarter release showed 561 plasma centers served, down 46 from a year earlier, even as plasma revenue rose 21.4% to $13.04 million.
Price setup
The shares closed at $14.96 on 8 October 2026, a 52-week closing high in adjusted daily closes. The prior closing high was $14.81 on 5 October 2026, followed by a pullback to $14.36 on 6 October 2026. MarketBeat put the 50-day moving average at $12.75 and the 200-day at $8.98 on 8 October 2026, so the price sits well above both rising averages.
Crowding signs are visible. The shares trade at the consensus target, RSI is above 77, and officers have sold through August and September. Volume was 873,426 shares on 8 October 2026 per MarketBeat, against 2,537,830 shares on the 2 October 2026 breakout session. A weekly close below $12.00 would put the shares under the 50-day average and give back most of the September advance.
Catalysts, next 30 days
- ~21 October 2026, est.: Paysign announces its third-quarter earnings date and call. The company announced the second-quarter call on 14 July 2026, three weeks before the 5 August 2026 report. No third-quarter date was confirmed as of 9 October 2026.
- ~11 November 2026, est.: Third-quarter 2026 report, just outside the 30-day window. Calendars range from 10 November 2026 (StockAnalysis) to 12 November 2026, and the prior-year call was 12 November 2025. The case turns on the active-program count against 165–170 and revenue against $28.5–30.0 million.
What would change the view
The case breaks if the 30 September 2026 active-program count comes in below 165, the low end of guidance, because program growth is the model behind the pharmaceutical revenue. Third-quarter revenue below $28.5 million, or any cut to the $114–117 million full-year outlook, would also break it.
On price, a weekly close below $12.00 would end the thesis. That level sits under the 50-day moving average, which MarketBeat put at $12.75 on 8 October 2026. A covering firm cutting its rating or its $15 target, or new officer sales filed without a Rule 10b5-1 plan footnote, would weaken the case without ending it.
What it trades with
Paysign trades mainly on company news: earnings releases, guidance changes and analyst target moves. MarketBeat listed a beta of 0.83 on 8 October 2026, a low reading for a stock up 64.0% in three months. Its pharmaceutical segment depends on drug-maker spending on copay assistance, which ties it to US drug-pricing and copay policy. Its plasma segment depends on donor-compensation volumes at collection operators, chiefly CSL, Grifols and Takeda's BioLife, per the company's FY2024 10-K. As a small-cap stock with thin volume, it can also move with small-cap risk appetite.
Notes
- Paysign is a small-cap stock with thin daily volume; single-session moves of 15–25% on earnings releases and 8-K filings have occurred in this name.
- Some insider sales run under Rule 10b5-1 plans (CEO Mark Newcomer adopted one on 12 September 2025); each Form 4 footnote shows whether a sale was pre-planned.
- Paysign reports both GAAP and adjusted earnings, and they differ materially; full-year 2026 GAAP EPS guidance is $0.35–0.37.
- Plasma revenue is concentrated in a few collection-center operators, chiefly CSL, Grifols and Takeda/BioLife, per the company's FY2024 10-K.
- Analyst coverage is small, so a single initiation or target change moves the published consensus target by a wide margin.
Related · shared themes
INTU
Intuit Inc.
Intuit's QuickBooks became a launch connector inside Meta's Muse agent on 6 October 2026, easing the main fear that AI agents would take its customers. The fiscal Q1 report expected around 19 November 2026 shows whether new-customer growth restarts.
MA
Mastercard Incorporated
Mastercard's earnings are growing faster than its share price, which stablecoin and swipe-fee legislation fears hold back; the 29 October 2026 third-quarter report shows whether 12% cross-border and 20% services growth held up.
OPRT
Oportun Financial Corporation
Oportun Financial's shares closed at a 52-week high of $8.66 on 8 October 2026 after a profit repair that beat guidance in Q2 2026; the Q3 report, estimated for 3 November 2026, decides whether charge-offs near 11.0% and adjusted EBITDA of at least $43 million confirm it.
PMTS
CPI Card Group Inc.
CPI Card Group's free-cash-flow and debt-reduction case holds with the shares at $25.00 on 8 October 2026; the third-quarter report, expected 3 November 2026 or 11-04, decides whether margins back the $45–50 million cash forecast.